Olema Pharmaceuticals Executive Compensation (FY25)
OLMA · Executive and director compensation, fiscal 2024 to 2025
The paid brief on Olema Pharmaceuticals
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): June 23, 2026
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
94 figures on this page: 89 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
More on Olema Pharmaceuticals
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Sean Bohen: $8,130,556 → $3,178,990 (60.9% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Olema Pharmaceuticals' chief executive and what were they paid?
Total compensation for Sean Bohen, President and Chief Executive Officer, came to $3,178,990 in fiscal 2025. Compared with the $8,130,556 reported for fiscal 2024, Bohen's total was 60.9% lower.
What was Olema Pharmaceuticals' say-on-pay result?
The say-on-pay proposal drew 99.0% support at the meeting held June 17, 2026 for fiscal 2025.
Which companies are in Olema Pharmaceuticals' peer group?
The disclosed peer group names Alector, Alumis, Amylyx Pharmaceuticals (amlx), AnaptysBio and Annexon, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sean Bohen President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Shane Kovacs Chief Operating and Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sean Bohen President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Shawnte Mitchell Chief Legal Officer and Corporate Secretary | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Shane Kovacs Chief Operating and Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Sean Bohen | Option | — | — | — | — | — | — | ◇ |
| Shane Kovacs | Option | — | — | — | — | — | — | ◇ |
| Shawnte Mitchell | Option | — | — | — | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Shane Kovacs | Option | ◇ | — | ◇ | 1/31/2032 |
| Option | ◇ | — | ◇ | 2/1/2034 | |
| Option | ◇ | — | ◇ | 2/28/2035 | |
| Option | ◇ | — | ◇ | 1/31/2033 | |
| Shawnte Mitchell | Option | ◇ | — | ◇ | 2/28/2035 |
| Sean Bohen | Option | ◇ | — | ◇ | 2/1/2034 |
| Option | ◇ | — | ◇ | 2/28/2035 | |
| Option | ◇ | — | ◇ | 1/31/2033 | |
| Option | ◇ | — | ◇ | 1/31/2032 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Ian Clark | ◇ | — | ◇ | — | — | — | ◇ |
Cynthia Butitta | ◇ | — | ◇ | — | — | — | ◇ |
Yi Larson | ◇ | — | ◇ | — | — | — | ◇ |
Andrew Rappaport | ◇ | — | ◇ | — | — | — | ◇ |
Scott Garland | ◇ | — | ◇ | — | — | — | ◇ |
Sandra Horning, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Gorjan Hrustanovic, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Graham Walmsley, M.D., Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Cyrus L. Harmon, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Raman (Dr.) and Sean Bohen, M.D., Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Alector ALEC
- Alumis ALMS
- Amylyx Pharmaceuticals (amlx) AMLX
- AnaptysBio ANAB
- Annexon ANNX
- Arcturus Therapeutics ARCT
- Arcus Biosciences RCUS
- Arvinas ARVN
- Aura Biosciences AURA
- Cogent Biosciences COGT
- Cullinan Therapeutics CGEM
- Erasca ERAS
- Inhibrx Biosciences INBX
- KalVista Pharmaceuticals KALV
- Keros Therapeutics KROS
- Kodiak Sciences KOD
- Kura Oncology KURA
- MeiraGTx MGTX
- Nuvation Bio NUVB
- ORIC Pharmaceuticals ORIC
- Praxis Precision Medicines PRAX
- Relay Therapeutics RLAY
- Syndax Pharmaceuticals SNDX
- Terns Pharmaceuticals TERN
- Verastem VSTM
- Vir Biotechnology VIR
- Xencor XNCR
- Zenas BioPharma ZBIO
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 17, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 10, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 13, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 15, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 16, 2022 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Olema Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Olema Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
94 figures on this page: 89 cited to the filing that reported them, 5 calculated from figures it prints.
89 cited to the filing
5 calculated from the filing
Documents cited
- 0001193125-26-279483
- 0001193125-26-191956Director Compensation for 2025 · EXECUTIVE COMPENSATION · Outstanding Equity Awards at December 31, 2025 · Summary Compensation Table
- 0000950170-25-086256
- 0000950170-25-059348Summary Compensation Table
- 0000950170-24-073749
- 0001558370-23-011291
- 0001558370-22-010221Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Olema Pharmaceuticals executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/OLMA (accessed 2026).
Short form: data: Velarion
The paid brief for Olema Pharmaceuticals
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Olema Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Olema Pharmaceuticals discloses
The companies named in OLMA's own disclosed peer group.
AlectorAlumisAmylyx Pharmaceuticals (amlx)AnaptysBioAnnexonArcturus TherapeuticsArcus BiosciencesArvinasAura BiosciencesCogent BiosciencesCullinan TherapeuticsErascaInhibrx BiosciencesKalVista PharmaceuticalsKeros TherapeuticsKodiak SciencesKura OncologyMeiraGTxNuvation BioORIC PharmaceuticalsPraxis Precision MedicinesRelay TherapeuticsSyndax PharmaceuticalsTerns Pharmaceuticals
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}